Today for AI
HOT RADAR
industryHEAT 11.0°

AI CLUSTERED EVENT · 10/8/2026

Isomorphic Labs Seeks Funding at $40-50 Billion Valuation Amid AI Drug Discovery Boom

1 reports archived1 independent sourcesupdated 10/8/2026, 14:33:15
Synthesis & Latest Updates
1 Sources Cross-Validated

Isomorphic Labs, the Alphabet subsidiary led by Nobel laureate Demis Hassabis, is in early talks for a new funding round targeting a valuation of $40-50 billion. Following a $2.1 billion Series B in May 2024, this significant valuation jump highlights intense investor confidence in AI-driven drug discovery, although the sector remains in its early stages prior to widespread clinical trial success.

LATEST/Isomorphic Labs, the Alphabet subsidiary led by Nobel laureate Demis Hassabis, is in early talks for a new funding round targeting a valuation of $40-50 billion. Following a $2.1 billion Series B in May 2024, this significant valuation jump highlights intense investor confidence in AI-driven drug discovery, although the sector remains in its early stages prior to widespread clinical trial success.

TIMELINECoverage timeline

Total 1 reports · Latest first
  1. IT之家 · 智能时代T2·68 pts

    Isomorphic Labs Seeks Funding at $40-50 Billion Valuation Amid AI Drug Discovery Boom

    Original: 消息称 Alphabet 旗下 AI 药物研发企业 Isomorphic Labs 寻求以 400~500 亿美元估值融资

    • Isomorphic Labs is negotiating a new funding round with a target valuation between $40 and $50 billion.
    • The company completed a $2.1 billion Series B in May 2024, demonstrating rapid valuation growth.
    • Despite high capital enthusiasm, AI drug discovery still faces significant technical and regulatory hurdles before clinical translation and market launch.